Study identifier:D4198C00001
ClinicalTrials.gov identifier:NCT02558894
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
No
MEDI4736 monotherapy, tremelimumab+MEDI4736
All
65
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2018 by AstraZeneca
AstraZeneca
-
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B.
Location
Location
Seoul, Republic of Korea, 03080
Location
Seoul, Republic of Korea, 135-710
Location
Seoul, Republic of Korea, 03722
Location
Seongnam-si, Republic of Korea, 463-707
Location
Seoul, Republic of Korea, 06591
Location
New York, NY, United States, 10065
Location
Tampa, FL, United States, 33612
Location
Ottawa, ON, Canada, K1H 8L6
Arms | Assigned Interventions |
---|---|
Experimental: MEDI4736 monotherapy MEDI4736 via IV infusion. | Drug: MEDI4736 monotherapy MEDI4736 via IV infusion. Other Name: NA |
Experimental: tremelimumab+MEDI4736 MEDI4736+tremelimumab via IV infusion. | Drug: tremelimumab+MEDI4736 tremelimumab+MEDI4736 via IV infusion. Other Name: NA |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.